Skip to content

Clinical Pipeline

Researchers at the LIT work tirelessly to develop novel therapeutics that will go on to improve patients' lives. Our portfolio of preclinical development projects includes:

  1. Stem-like memory CAR T cells – CD22/CD19-bispecific CD8+ Tscm cells for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
  2. Functionally empowered TCR transgenic T cells – NY-ESO-1-TCR-redirected Tscm cells overexpressing human miR-155 SNP rs377265631 for the treatment of relapsed or treatment-refractory sarcoma.
  3. AIR Tregs – Treatment of GvHD and treatment-refractory autoimmune disease with redirected regulatory T cells expressing artificial immune receptors which recognize inflammation-associated ligands in inflamed tissue.
  4. CAR T cells with therapeutic payload – Treatment of advanced GI cancer with CEA-specific CAR T cells secreting CEACAM6 immune checkpoint-blocking antibodies upon tumor cell recognition.
  5. CAR T cells with improved functional activity – CD30/CEA specific CAR T cells for the treatment of unresectable liver metastases from colorectal cancer.